Prime Editing: A Revolutionary Technology for Precise Treatment of Genetic Disorders
Cell Proliferation · 2025-04 · 58 (4)
DOI: 10.1111/cpr.13808 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cell Proliferation, online erschienen am 27.02.2025. Verfasst von Mengyao Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China. Hauptthemen laut MEDLINE: Gene Editing, Genetic Diseases, Inborn, Genetic Therapy. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 179 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Noncommunicable Chronic Diseases-National Science and Technology Major Project, Initiative Scientific Research Program, Institute of Zoology, Chinese Academy of Sciences, Beijing-Tianjin-Hebei Basic Research Cooperation Project.
Abstract (Originalsprache)
Genetic diseases have long posed significant challenges, with limited breakthroughs in treatment. Recent advances in gene editing technologies offer new possibilities in gene therapy for the treatment of inherited disorders. However, traditional gene editing methods have limitations that hinder their potential for clinical use, such as limited editing capabilities and the production of unintended byproducts. To overcome these limitations, prime editing (PE) has been developed as a powerful tool for precise and efficient genome modification. In this review, we provide an overview of the latest advancements in PE and its potential applications in the treatment of inherited disorders. Furthermore, we examine the current delivery vehicles employed for delivering PE systems in vitro and in vivo, and analyze their respective benefits and limitations. Ultimately, we discuss the challenges that need to be addressed to fully unlock the potential of PE for the remission or cure of genetic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
- Key Laboratory of Organ Regeneration and Reconstruction, Institute of Zoology, Chinese Academy of Sciences, Beijing, China.
- Beijing Institute for Stem Cell and Regenerative Medicine, Beijing, China.
- University of Chinese Academy of Sciences, Beijing, China.
- Department of Biomedical Engineering, College of Future Technology, Peking University, Beijing, China.
- Beijing Advanced Center of RNA Biology, Peking University, Beijing, China.
ORCID-Profile: Mengyao Li, Yi Lin, Qiang Cheng, Tuo Wei
Förderung
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Initiative Scientific Research Program, Institute of Zoology, Chinese Academy of Sciences
- Beijing-Tianjin-Hebei Basic Research Cooperation Project
- the "Open Competition to Select the Best Candidates" Key Technology Program for Nucleic Acid Drugs of NCTIB
- the Fundamental Research Funds for the Central Universities, Peking University
- the Beijing Life Science Academy
- China Postdoctoral Science Foundation
Zitieren
APA
Li, M., Lin, Y., Cheng, Q., & Wei, T. (2025). Prime Editing: A Revolutionary Technology for Precise Treatment of Genetic Disorders. Cell Proliferation, 58(4). https://doi.org/10.1111/cpr.13808
Vancouver
Li M, Lin Y, Cheng Q, Wei T. Prime Editing: A Revolutionary Technology for Precise Treatment of Genetic Disorders. Cell Proliferation. 2025;58(4). doi:10.1111/cpr.13808
BibTeX
@article{Li2025,
author = {Li, Mengyao and Lin, Yi and Cheng, Qiang and Wei, Tuo},
title = {Prime Editing: A Revolutionary Technology for Precise Treatment of Genetic Disorders},
journal = {Cell Proliferation},
year = {2025},
volume = {58},
number = {4},
doi = {10.1111/cpr.13808}
}
EUVIMED